Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)